Filing Details

Accession Number:
0000899243-20-022200
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-12 21:04:57
Reporting Period:
2020-08-11
Accepted Time:
2020-08-12 21:04:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651431 Checkmate Pharmaceuticals Inc. CMPI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202793 Michael Powell C/O Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
Yes No Yes No
1245624 James Healy C/O Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612133 Sofinnova Venture Partners Ix, L.p. C/O Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612134 Sofinnova Management Ix, L.l.c. C/O Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-11 3,473,374 $0.00 3,473,374 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-08-11 133,333 $15.00 3,606,707 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2020-08-11 12,500,000 $0.00 1,671,771 $0.00
Common Stock Series B Preferred Stock Disposition 2020-08-11 8,753,350 $0.00 1,314,165 $0.00
Common Stock Series C Preferred Stock Disposition 2020-08-11 3,644,624 $0.00 487,438 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  3. The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.